IRIX Pharmaceuticals develops, tests, and manufactures drugs and drug ingredients for pharmaceutical companies. Services include discovery support, process research and development, clinical supply, manufacturing, and commercial production. It also helps clients work through the regulatory red tape. The company maintains three facilities in South Carolina. Its Florence facility has laboratories devoted to developing and testing new candidates. IRIX was formed in 1996 by CEO Guy Steenrod, former president of Roche Carolina -- the process discovery and development arm of Roche Pharmaceutical -- and a group of South Carolina investors.

Microbix makes biotherapeutic drugs, vaccines, and infectious disease diagnostics for multinational manufacturers. The company's pipeline includes leading generic drug candidate ThromboClear for the treatment of coronary artery thrombosis and the FDA-approved drug urokinase, used to treat pulmonary embolism. Microbix has also submitted patents for its Sperm Sexing Technology, which enables livestock producers to predetermine offspring gender prior to conception. In 2008 Microbix entered into an agreement with China to build one of the world's largest influenza manufacturing plants to produce flu vaccines.

ADVENTRX Pharmaceuticals, Inc. company was founded in 1995 is based in San Diego, California. ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

Novartis Corporation has what the doctor ordered. As the North American headquarters of Switzerland-based Novartis AG, the unit handles administration, sales, and marketing for a vast product line of prescription drugs, consumer health products, vaccines, and veterinary products. But wait, there is more! Novartis Corporation also oversees the Novartis Institutes for Biomedical Research, which is headquartered in the US. Novartis Corporation headlines dozens of US business units including CIBA Vision, Novartis Pharmaceuticals, and the US operations of its Sandoz generics business.

Blansett Pharmacal Co., Inc. company's products include respiratory drugs Prolex and Nalex, tension headache remedy Anolor, and swimmer's ear treatment Cortane. Blansett also makes medications for women's health and hemorrhoids. On top of developing its own products, the company markets under-promoted products developed by other pharmaceutical companies. Blansett Pharmacal was founded in 1982 in North Little Rock, Arkansas; its products are distributed throughout the US.

Mitsubishi Tanabe Pharma makes proprietary prescription pharmaceuticals in a number of therapeutic areas, including cardiovascular disease, diabetes, neuroscience, immunology, and oncology. In its home market, it sells products such as anticoagulant Anplag, anti-allergy medicine Talion, liver drug Urso, and neuroprotective agent Radicut. Its Benesis unit makes therapeutic plasma proteins such as albumin. The company markets and sells its products through in-house sales agents and distributors. Formerly Mitsubishi Pharma, the company merged with fellow Japanese drugmaker Tanabe Seiyaku and subsequently changed its name; Mitsubishi Chemical Holdings owns a majority stake in the new entity.

Sunesis Pharmaceuticals, Inc. company was founded in 1998 and is headquartered in South San Francisco, California. Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumor cancers. Its primary product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer in Phase 2 development stage. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in advanced platinum-resistant ovarian cancer patients. Sunesis Pharmaceuticals has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin.

Eisai Inc. develops and markets pharmaceuticals to treat a variety of ills. As the US pharmaceutical production arm of Eisai Co., its current product roster includes Alzheimer's treatment Aricept, Aciphex for acid reflux, anticoagulant Fragmin, and anti-convulsant Zonegran. It also maintains an extensive pipeline of potential drugs to address cancer, epilepsy, and severe infection. Subsidiaries Eisai Research Institute of Boston and Eisai Medical Research conduct drug development efforts in areas including oncology, neurology, and gastrointestinal ailments.

Galderma Laboratories, L.P., a dermatology company, engages in the research, development, and marketing of dermatology products. Its pharmaceutical and over-the-counter products include Differin, which is used to treat acne; MetroGel, MetroLotion, and MetroCream, to treat rosacea; Clobex lotion, which helps in controlling and treating moderate-to-severe plaque psoriasis; and Cetaphil, a line of cleansers and moisturizers. The company has operations in North America, Western Europe, Latin America, Asia, Australia, and Africa. It offers its services directly, and through sales representatives, as well as through special programs. The company was founded in 1961 as Owen Laboratories and changed its name to Galderma Laboratories, L.P. in 1981. The company is headquartered in Fort Worth, Texas. Galderma Laboratories, L.P. operates as a subsidiary of Galderma SA.

Roche NimbleGen, founded in 1999, serves clients such as academic institutions, government laboratories, and pharmaceutical companies. It is a part of Roche Diagnostics. Roche NimbleGen displays agility in testing DNA. Formerly NimbleGen Systems, the company develops products and services for the analysis of genomes, which include the complete genetic material of an organism. The company produces high-density arrays of long oligo probes offering the deep high quality information necessary to study genomic variation base on ist proprietary Maskless Array Sythesis technology. By understanding the nature and function of genomes, scientists are able to improve a variety of medical and agricultural products.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.